早期转换为基于贝拉塔塞普的免疫抑制疗法促进了移植接受者长期改善的移植功能
Mahmoudreza Moein1, Reut Hod Dvorai2, Benson W Li3
1Department of Surgery, Division of Transplantation, SUNY Upstate Medical University, Syracuse, NY, USA.
Transplant immunology
|July 1, 2023
概括
在移植后早期转换为贝拉塔塞普,显著改善了估计的膜过率 (eGFR). 晚期转换没有显示出显著的eGFR变化,但早期转换的接受基酸 (MPA) 的患者经历了更多的T细胞介导排斥.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫抑制是一种免疫抑制.
- 移植 移植 移植 移植
背景情况:
- 贝拉塔塞普特是一种有效的免疫抑制剂,用于移植接受者.
- 本研究评估了早期 (<6个月) 与晚期 (>6个月) 转换为基于贝拉塔塞普的免疫抑制的结果.
研究的目的:
- 在移植患者中,比较早期与晚期转换为贝拉的疗效.
- 评估转化时间对功能和移植存活的影响.
主要方法:
- 从成年移植患者 (2014-2022) 收集的前性数据的回顾性分析.
- 患者被分为早期 (<6个月) 和晚期 (>6个月) 转化组.
- 结果包括估计的淋巴细胞过率 (eGFR),移植存活率和排斥率.
主要成果:
- 早期转换 (n=33) 在一年内显示出显著的EGFR改善 (26.7至45.3毫升/分钟/1.73米2,p=0.0006).
- 晚期转换 (n=28) 具有微不足道的eGFR变化 (46.3至44.7毫升/分钟/1.73米2,p=0.72).
- 在两组中,全移植一年生存率为100%;患者生存率为90.9% (早期) 和100% (晚期). 在MPA的4个早期转换者和2个晚期转换者中发生了急性T细胞介导排斥 (ATMR).
结论:
- 与晚期转换相比,早期转换到移植后的贝拉 significantly显著增强了eGFR.
- 与基于塔克罗利斯的疗法相比,同时使用贝拉塔塞普和MPA可能会增加T细胞介导排斥的风险.
相关概念视频
01:28Kidney Transplant I: Introduction
29
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
29
01:26Kidney Transplant II: Surgical Procedure
36
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
36
01:16Kidney Transplant III: Nursing Management
41
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
41
01:40Cell-mediated Immune Responses
69.1K
Overview
69.1K
01:29Acute Kidney Injury III: Clinical Manifestations
40
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
40